Dosing referencenever gated · no calculator
What the label or the trial says.
Per peptide, the figure the drug label or the published trial gives, with the source beside it. Under many rows, the full protocols on file — starting dose, escalation, target, cycle — each badged FDA label, clinical trial or community protocol, and each linked to where it came from. Where there is nothing to cite, the row says so.
Read first · not dosing instructions
Educational and research reference only. Not medical advice, not a recommendation, and not dosing instructions for any person. Figures are reported from the cited source and may be wrong or out of date. Research peptides are not approved for human use. Adults 18+. Consult a licensed physician before any decision about your health.
Peptide · gradeWhat the label or trial saysSource
Cerebrolysingrade BCountry-specific protocolsPI
Product prescribing information
Product prescribing information
Protocols · 2 · trial / community
Clinical trialCARS post-stroke trial (Muresanu, Stroke 2016)
Once daily, 21 days
Start: 30 mL IV once daily, starting 24-72 h after stroke onset
Then: None
Target: 30 mL IV once daily for 21 days plus standardised rehabilitation
Start: 30 mL IV once daily, starting 24-72 h after stroke onset
Then: None
Target: 30 mL IV once daily for 21 days plus standardised rehabilitation
SourcePubMed 26564102 ↗
Community protocol — not clinically establishedCommunity guide — research-vial pattern
Daily
Start: 20 mg/day, week 1
Then: 24 mg week 2; 28 mg week 3
Target: 32 mg/day, week 4+
Start: 20 mg/day, week 1
Then: 24 mg week 2; 28 mg week 3
Target: 32 mg/day, week 4+
GHK-Cu (Copper peptide)grade CTopical concentrations vary by productProduct
Product labelling · topical
Product labelling · topical
Protocols · 2 · community
Community protocol — not clinically establishedCommunity guide — injectable
Daily; conservative tier 5 days on / 2 off
Start: Conservative 1.0 mg daily, 5 days on / 2 off, 4-week cycle
Then: Standard 1.0-1.5 mg daily continuous (4-6 weeks); higher end 1.5-2.0 mg daily continuous (6-8 weeks)
Target: "1-2 mg per day SubQ for a 4-8 week cycle"
Cycle: 4-8 weeks depending on tier
Start: Conservative 1.0 mg daily, 5 days on / 2 off, 4-week cycle
Then: Standard 1.0-1.5 mg daily continuous (4-6 weeks); higher end 1.5-2.0 mg daily continuous (6-8 weeks)
Target: "1-2 mg per day SubQ for a 4-8 week cycle"
Cycle: 4-8 weeks depending on tier
Community protocol — not clinically establishedCommunity guide — topical
Once or twice daily
Start: 1-2% facial, once or twice daily
Then: Not stated
Target: Typical formulations 1-3% by weight. Face 1-2%; scalp/hair 1-3% daily.
Cycle: Facial 8-12 weeks; scalp 12+ weeks ongoing
Start: 1-2% facial, once or twice daily
Then: Not stated
Target: Typical formulations 1-3% by weight. Face 1-2%; scalp/hair 1-3% daily.
Cycle: Facial 8-12 weeks; scalp 12+ weeks ongoing
Leptin / Metreleptingrade CProduct-specific dosing (specialist use)PI
Product prescribing information
Product prescribing information
Mazdutidegrade BPer local prescribing information where approvedPI
Product prescribing information
Product prescribing information
Protocols · 1 · trial
Clinical trialGLORY-1 (Ji, NEJM 2025)
Once weekly, 48 weeks
Start: 2 mg weekly for 4 weeks
Then: 4 mg arm: 4 mg for 44 weeks. 6 mg arm: 4 mg for 4 weeks, then 6 mg for 40 weeks.
Target: 4 mg or 6 mg weekly. 48-week weight change -11.00% and -14.01% vs +0.30% placebo.
Max: 6 mg weekly (maximum studied here)
Start: 2 mg weekly for 4 weeks
Then: 4 mg arm: 4 mg for 44 weeks. 6 mg arm: 4 mg for 4 weeks, then 6 mg for 40 weeks.
Target: 4 mg or 6 mg weekly. 48-week weight change -11.00% and -14.01% vs +0.30% placebo.
Max: 6 mg weekly (maximum studied here)
NAD+grade DOral/IV protocols vary; no single labeled dose for 'NAD+' productsPI
Product prescribing information
Product prescribing information
Protocols · 2 · trial / community
Clinical trialIV pharmacokinetic pilot (Grant, 2019)
Single infusion
Start: 750 mg IV over 6 h (n=8) vs saline (n=3)
Then: None
Target: Not a treatment regimen. No adverse events at an infusion rate of 2 mg/min.
Start: 750 mg IV over 6 h (n=8) vs saline (n=3)
Then: None
Target: Not a treatment regimen. No adverse events at an infusion rate of 2 mg/min.
Community protocol — not clinically establishedCommunity guide
SC 2-3x weekly; IV weekly to biweekly
Start: SC 50 mg, once to three times weekly (assessment phase)
Then: Increase by about 25 mg to 75 mg, 1-3x weekly
Target: SC 100 mg 2-3x weekly. IV 250-500 mg per session weekly or biweekly.
Cycle: 4-, 8- or 12-week frameworks; "No single established cycle exists"
Start: SC 50 mg, once to three times weekly (assessment phase)
Then: Increase by about 25 mg to 75 mg, 1-3x weekly
Target: SC 100 mg 2-3x weekly. IV 250-500 mg per session weekly or biweekly.
Cycle: 4-, 8- or 12-week frameworks; "No single established cycle exists"
Oxytocingrade CIndication-specific dosing (obstetrics)PI
Product prescribing information
Product prescribing information
Protocols · 3 · label / trial / community
FDA labelPitocin (obstetric: induction/augmentation of labour)
Continuous infusion titrated to uterine response
Start: Induction: 0.5-1 mU/min IV
Then: Increase by 1-2 mU/min at 30-60 min intervals until the desired contraction pattern
Target: Desired contraction pattern
Start: Induction: 0.5-1 mU/min IV
Then: Increase by 1-2 mU/min at 30-60 min intervals until the desired contraction pattern
Target: Desired contraction pattern
Clinical trialSOARS-B, autism (Sikich, NEJM 2021)
Daily, 24 weeks
Start: Titrated to target
Then: Not given in the summary
Target: 48 IU/day total. No significant difference in social or cognitive outcomes vs placebo.
Start: Titrated to target
Then: Not given in the summary
Target: 48 IU/day total. No significant difference in social or cognitive outcomes vs placebo.
SourcePubMed 34644471 ↗
Community protocol — not clinically establishedCommunity guide
Once daily (SC); per session (intranasal)
Start: SC low 100 mcg once daily
Then: SC moderate 200-300 mcg; upper 400-500 mcg once daily
Target: Intranasal 10-72 IU/session in research (24 IU commonly cited)
Cycle: Short 1-2 weeks; standard 4-6 weeks then 1-2 weeks off
Start: SC low 100 mcg once daily
Then: SC moderate 200-300 mcg; upper 400-500 mcg once daily
Target: Intranasal 10-72 IU/session in research (24 IU commonly cited)
Cycle: Short 1-2 weeks; standard 4-6 weeks then 1-2 weeks off
Pinealongrade BPer local prescribing information where approvedPI
Product prescribing information
Product prescribing information
Protocols · 1 · community
Community protocol — not clinically establishedCommunity guide
Once daily, morning or early afternoon
Start: 1.0 mg SC daily, days 1-5
Then: 1.5 mg days 6-14
Target: 2.0 mg days 15-20
Cycle: 10-20 days (some to 28); 2-3 months off
Start: 1.0 mg SC daily, days 1-5
Then: 1.5 mg days 6-14
Target: 2.0 mg days 15-20
Cycle: 10-20 days (some to 28); 2-3 months off
Somatropingrade AProduct-specific dosing (endocrinology)PI
Product prescribing information
Product prescribing information
Protocols · 2 · label / community
FDA labelGenotropin, adult GH deficiency
Weekly dose divided into 6 or 7 daily injections
Start: Non-weight-based: about 0.2 mg/day (range 0.15-0.30 mg/day). Weight-based: not more than 0.04 mg/kg/week.
Then: Non-weight-based: increase every 1-2 months by about 0.1-0.2 mg/day per clinical response and serum IGF-I. Weight-based: may increase at 4-8 week intervals.
Target: Per clinical response and serum IGF-I
Max: Weight-based: not more than 0.08 mg/kg/week
Start: Non-weight-based: about 0.2 mg/day (range 0.15-0.30 mg/day). Weight-based: not more than 0.04 mg/kg/week.
Then: Non-weight-based: increase every 1-2 months by about 0.1-0.2 mg/day per clinical response and serum IGF-I. Weight-based: may increase at 4-8 week intervals.
Target: Per clinical response and serum IGF-I
Max: Weight-based: not more than 0.08 mg/kg/week
Community protocol — not clinically establishedCommunity guide
Daily, 5-7 days/week
Start: 1-2 IU daily, SC, empty stomach
Then: "Start at 1-2 IU and titrate based on IGF-1 levels"
Target: Wellness 1-2 IU/day; body recomposition 2-4 IU/day; recovery 2-3 IU/day
Cycle: 3-6+ months continuous
Start: 1-2 IU daily, SC, empty stomach
Then: "Start at 1-2 IU and titrate based on IGF-1 levels"
Target: Wellness 1-2 IU/day; body recomposition 2-4 IU/day; recovery 2-3 IU/day
Cycle: 3-6+ months continuous
Thymosin Alpha-1 (Thymalfasin)grade BProduct/country-specific dosingPI
Product prescribing information
Product prescribing information
Protocols · 2 · label / community
Label — Zadaxin (approved outside the US; not FDA)Zadaxin (chronic hepatitis B)
Twice weekly, about 3-4 days apart
Start: 1.6 mg (900 mcg/m2) SC twice a week
Then: None
Target: 1.6 mg SC twice a week for 6 to 12 months. Under 40 kg: 40 mcg/kg.
Start: 1.6 mg (900 mcg/m2) SC twice a week
Then: None
Target: 1.6 mg SC twice a week for 6 to 12 months. Under 40 kg: 40 mcg/kg.
SourceRxList — Zadaxin ↗
Community protocol — not clinically establishedCommunity guide
Twice weekly
Start: 1.6 mg SC twice weekly (same as the label)
Then: None
Target: 1.6 mg twice weekly
Cycle: 6 months (hep B), up to 12 months; 4-12 weeks for "general immune support" (community, no label or trial basis)
Start: 1.6 mg SC twice weekly (same as the label)
Then: None
Target: 1.6 mg twice weekly
Cycle: 6 months (hep B), up to 12 months; 4-12 weeks for "general immune support" (community, no label or trial basis)
No body weight, no goals, no calculator: the same text for every reader. A figure without its source is indistinguishable from a recommendation, so every row and every protocol carries one. Community protocols are what guides and vendors publish, not what any trial established. Where nothing can be cited, the row says so.